Clinical Trial Update: Health Evaluation of Abilify Long-term Therapy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating long-term Abilify (aripiprazole) therapy for schizophrenia and schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Taiwan Otsuka Pharm. Co., Ltd | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED